mRNA
Germany’s CureVac announced it has enrolled the first volunteer in the pivotal Phase IIb/III trial of its own mRNA vaccine candidate, CVnCoV against COVID-19.
Manufacturing capacity is often decried as a major bottleneck in administering COVID-19 vaccines to a global population of 7.8 billion. For mRNA vaccines, the bottleneck is the availability of raw materials, not bioreactors.
It isn’t often that a contestant pulls ahead in a major contest and their competitor wins too, but Moderna – along with other COVID-19 vaccine contenders – will take it.
The company is genetically programming RNA not just to deliver a gene of interest, but to control the location, timing and intensity of therapeutic protein expression using mRNA-encoded logic circuits.
The two companies will combine their mRNA research to develop the potential vaccines across a range of infectious disease pathogens.
Moderna’s mRNA Zika vaccine data is becoming helpful in the development of the COVID-19 vaccine. The company is using the elements to faster the process of producing the vaccine.
The two companies will focus on BioNTech’s BNT162, an mRNA-based vaccine candidate.
The companies intend to push the vaccine candidate into human trials by April of this year, subject to regulatory approval.
Under a Technology License Agreement with the Houston Methodist Research Institute, Contract Developer and Manufacturer VGXI Achieves Key Milestones with Establishment of Pilot Production Capabilities for RNA-Based Medicines.
Wouldn’t it be amazing to be able to see a protein being made in a cell in real time? And wouldn’t it be even better if you could use that capability to discover new drugs to previously “undruggable” targets, creating new medicines? Well that’s exactly what Anima Biotech is aiming to do.
PRESS RELEASES